Medicinal composition containing angiotensin II receptor agonist and fibric acid compound

A receptor antagonist, angiotensin technology, applied in the field of pharmaceutical preparation, can solve the problem of not finding angiotensin II receptors, etc., and achieve the effects of delaying cardiovascular and cerebrovascular diseases, preventing or delaying damage, and taking medicines conveniently.

Active Publication Date: 2007-01-10
SHENZHEN AUSA PHARM CO LTD +2
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] In the patent and scientific literature, no combination of angiotensin II receptors, antagonists and phenoxyacids is found for the prevention and treatment of hypertension with hyperlipidemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1. Preparation of Compound Irbesartan Fenofibrate Tablets Containing 75mg Irbesartan and 200mg Micronized Fenofibrate

[0033] Prescription: Irbesartan 75g

[0034] Micronized Fenofibrate 200g

[0035] Lactose 50g

[0036] Microcrystalline Cellulose 50g

[0037] Low-substituted hydroxypropyl cellulose 40g

[0038] Proper amount of povidone aqueous solution

[0039] Magnesium Stearate 1%

[0040] Preparation method: crush the raw and auxiliary materials through an 80-mesh sieve, and dry for later use. Take 75g irbesartan, 200g micronized fenofibrate, add 50g lactose, 50g microcrystalline cellulose, and 40g low-substituted hydroxypropyl cellulose, mix evenly according to the method of equal increase, and prepare with 10% povidone aqueous solution into soft material, granulate with 20 mesh sieve, dry at 60°C for about 2 hours, granulate with 20 mesh sieve, control the moisture content of the granules to 2-3%, mix the dried gr...

Embodiment 2

[0041] Example 2. Preparation of Compound Irbesartan Fenofibrate Tablets Containing 150mg Irbesartan and 200mg Micronized Fenofibrate

[0042] Prescription: Irbesartan 150g

[0043] Micronized Fenofibrate 200g

[0044] Microcrystalline Cellulose 40g

[0045] Starch 20g

[0046] Sodium carboxymethyl starch 40g

[0047] 10% starch slurry appropriate amount

[0048] Magnesium Stearate 1%

[0049] Preparation method: crush the original and auxiliary materials through a 120-mesh sieve, weigh the prescription amount of irbesartan, micronized fenofibrate, microcrystalline cellulose, starch and sodium carboxymethyl starch, crush and sieve, mix evenly, and use an appropriate amount of 10% starch slurry made into a soft material, granulated, dried at 40°C to 60°C until the water content is about 3%, taken out, sized, mixed evenly with an appropriate amount of magnesium stearate, and pressed into 1000 tablets are available.

Embodiment 3

[0050] Example 3. Preparation of compound irbesartan fenofibrate tablets containing 150mg irbesartan and 300mg fenofibrate

[0051] Prescription: Irbesartan 150g

[0052] Fenofibrate 300g

[0053] Microcrystalline Cellulose 50g

[0054] Low-substituted hydroxypropyl cellulose 50g

[0055] Micropowder silica gel amount

[0056] Magnesium Stearate Appropriate amount

[0057] Preparation method: crush the original and auxiliary materials through a 120-mesh sieve, weigh the prescription amount of irbesartan, fenofibrate, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, micronized silica gel and magnesium stearate, and mix well , The powder is directly pressed into 1000 pieces.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses a medicine composition. Said medicine composition includes 4-600 mg of one of angiotensin II receptor antagonist and its active metabolic product, salts or esters, 100-1200 mg one of phenoxy acid compound and its active metabolic product, salts or esters and pharmaceutically-acceptable carrier. Said invention also provides the application of said medicine composition in preparation of medicine for preventing, curing and delaying hypertension and / or hyperlipemia and angiocardiopathy and cerbrovascular diseases due to hypertension or / and hyperlipemia.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing angiotensin II receptor antagonist and phenoxy acid compound, and the application of the pharmaceutical composition in preparing medicine. belongs to the field of pharmacy. Background technique [0002] Epidemiological studies have found that many people have high blood pressure and high blood lipids at the same time, and these people have a high risk of cardiovascular diseases such as coronary heart disease, myocardial infarction, and stroke, and cardiovascular diseases account for the first cause of human death. It is estimated that 30 million American patients have been diagnosed with these two high-risk factors; in China, a cross-sectional survey of 711 hypertensive patients with hyperlipidemia found that 186 hypertensive patients with hyperlipidemia, the disease The rate is 26.2%, which is significantly higher than the population level; and the prevalence rate of cardiovascular and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/4166A61K9/16A61K9/20A61K9/48A61P3/06A61P3/04A61P9/10A61P9/12
Inventor 陈光亮王琳琳
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap